Biochip Array Technology Detects Drugs in Oral Fluid

Matrix dedicated kits ensure reliable assay performance including good specificity, even at lower drug concentrations.

Randox Laboratories (Crumlin, United Kingdom) biochip array technology offers a diagnostic grade testing solution with dependable and reproducible results. The Biochip arrays provide a rapid turnaround time, which is advantageous for onsite workplace drug testing. In comparison, a four-plate automated enzyme linked immunosorbent assay (ELISA) system requires thirteen times longer to process the same results.

A point of collection biochip analyzer was recently launched by Randox--the “Evidence MultiStat,” which processes multiple results in less than twenty minutes. The Biochip platform is multimatrix; therefore, a number of sample types including oral fluid, whole blood, urine, and postmortem tissue can be run on the system. The Randox line of Evidence immunoassay analyzers generate quality control data automatically with every run, ensuring that each test has been carried out successfully.

Randox biochip arrays meet the limit of detection requirements for both the European Workplace Drug Testing Society (EWDT) guidelines for oral fluid testing (2010) and the Australian and New Zealand procedures for specimen collection and the detection and quantification of drugs in oral fluid AS 4760-2006 (2006).

Testing of oral fluid specimens is becoming increasingly popular in the workplace, prisons, and in drug rehabilitation clinics. With a number of benefits to be gained from onsite testing, oral fluid will continue to be put into practice for drugs of abuse screening. As the prevalence of designer drugs and new variations of drugs enter the market, workplace drug testing is set to increase in a bid to detect and deter use. Oral fluid testing is also used as an aid in clinical diagnosis.

Related Links:
Randox Laboratories
European Workplace Drug Testing Society